TENS Treatment Plus Ibuprofen for the Treatment of Acute Back Pain in the ED

May 8, 2017 updated by: Paul Dominici, Albert Einstein Healthcare Network

Double-blind, Randomized, Placebo Controlled Trial of Transcutaneous Electrical Nerve Stimulation (TENS) Treatment Plus Ibuprofen for the Treatment of Acute Back Pain in the Emergency Department

Patients presenting to the ED with a chief complaint of acute low back pain and whom the providing physician feels symptomatic treatment is appropriate in the ED will be screened for inclusion in the study. The purpose of the study is to compare Transcutaneous Electrical Nerve Stimulation (TENS) as an adjunct to ibuprofen in the treatment of acute low back pain in the emergency department. Therefore, the aim of this prospective, randomized, double blind study is to evaluate the efficacy of ED administered TENS in acute low back pain patients during their ED visit.

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Detailed Description

The study is a double blind, randomized, placebo controlled trial. One group will receive ibuprofen and TENS. The comparison group will receive ibuprofen and sham TENS. The study primary endpoint is change in pain level on Visual Analog Scale score at 45-60 minutes after TENS start.

This is a two-arm, double blind, randomized control trial evaluating the patient perceived improvement in back pain. Patients will first fill out a Visual Analog Scale (VAS).

Patients will be randomized to one of two arms. Ibuprofen 800 mg, plus sham TENS for 45 minutes Ibuprofen 800 mg, plus TENS for 45 minutes

Patients will be given a 2nd VAS scale up to 15 minutes after the end of the TENS session. After the second VAS the patients will be finished with the study procedures and can be continued to be cared as per the discretion of their treating physician.

Our intention is to detect a 20% reduction in pain by VAS with a common standard deviation equal to the difference at the p = 0.05 level with a power of 80% using an analysis of variance (ANOVA). The calculated sample size required 28 patients per group. Considering the uncertain dropout rate, the investigators decided to enroll at least 66 patients. Baseline characteristics will be calculated to determine if groups are equal. A two-way repeated-measures ANOVA will be used to test both a trial effect and a group effect (SPSS 20, SPSS Inc., Chicago, IL). Data will be presented as means with standard deviations with 95% confidence intervals. A p< 0.05 was considered statistically significant.

Study Type

Interventional

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19141
        • Albert Einstein Healthcare Network

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Patients 18 years to 65 years of age presenting to the emergency room with a primary complaint of low back pain.
  2. Patient is receiving 800mg dose of ibuprofen as part of their treatment regimen for back pain
  3. Back pain new in the last 48 hours
  4. Deemed by the treating physician to have musculoskeletal back pain, and no central/peripheral nervous system pathology as the cause of their pain.

Exclusion Criteria:

  1. Allergy to ibuprofen.
  2. Hypotension (MAP <65 or Systolic BP <100), fever, tachycardia
  3. Paresthesias, isolated motor weakness, or objective sensory deficit on physical exam
  4. Radicular symptoms
  5. Urinary incontinence or retention
  6. Bowel incontinence
  7. Unexplained weight loss of >15 lbs in the last 3 months.
  8. Multiple primary complaints in the ED.
  9. Received Analgesia other than Ibuprofen as part of their ED work up.
  10. Taken prescription strength pain medication within the last 12 hours for any condition.
  11. History of active malignancy, HIV, organ transplantation, active hemodialysis
  12. Currently pregnant
  13. Nursing home residents
  14. Currently in police custody

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Ibuprofen and TENS plus
Patients will receive 45 minutes of TENS therapy. All patients will receive ibuprofen.
Transcutaneous Electrical Nerve Stimulation
Placebo Comparator: Ibuprofen and Sham TENS plus
Patients will receive 45 minutes of sham TENS therapy. All patients will receive ibuprofen.
Transcutaneous Electrical Nerve Stimulation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in visual analog scale (VAS)
Time Frame: 0 minutes, 45 minutes
Patients will have a baseline and 45 minutes VAS performed
0 minutes, 45 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Treatment failure
Time Frame: 45 minutes
Patients requiring rescue medication after 45 minute treatment will be considered treatment failures and will receive further non study related treatment at the discretion of the treating physician
45 minutes
Adverse events
Time Frame: 60 minutes
Any reactions to TENS application
60 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Paul G Dominici, MD, Albert Einstein Healthcare Network

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 24, 2016

Primary Completion (Actual)

June 24, 2016

Study Completion (Actual)

June 24, 2016

Study Registration Dates

First Submitted

November 19, 2015

First Submitted That Met QC Criteria

November 19, 2015

First Posted (Estimate)

November 23, 2015

Study Record Updates

Last Update Posted (Actual)

May 10, 2017

Last Update Submitted That Met QC Criteria

May 8, 2017

Last Verified

March 1, 2017

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HN4810

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Low Back Pain

Clinical Trials on TENS

3
Subscribe